Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Pediatric Expansion Study of the Sentio System

A legfontosabb adatok

Ki végzi
Oticon Medical
Hol
Egyesült Királyság, Hollandia és Spanyolország8 helyszín, 3 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
50 fő, tervezett
Kezdés
2025. ápr. 30.
Várható befejezés
2027. júl. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Active transcutaneous bone conduction system
A regiszteradat frissítve
2026. augusztus 14.

Ki vehet részt

Életkor
3 év – 11 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Signed Informed Consent Form (depending on age of child, signed by parent or legal guardian and child)
  • Subject aged 3 to 11 years
  • Subject with:; 3.1 conductive or mixed hearing losses with pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear better than or equal to 45 dB HL; 3.2 OR subject who has a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. SSD). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz) 3.3 OR subject indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS
  • Subject and parent or legal guardian have the ability and willingness to comply with investigational procedures/ requirements, as determined by the investigator
  • Subject with prior experience of amplified sound through a properly fitted hearing aid, a CROS device, or a non-surgical bone anchored solution (e.g. softband)
  • For subject with conductive or mixed hearing losses, ensure sufficient air bone gap (ABG) at the ear to be implanted
  • Sufficient bone quality/quantity/depth or skull size for implantation of a Sentio Ti implant as assessed according to clinical practice

Ki nem vehet részt

  • Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator
  • Subject that has received radiotherapy in the area of implantation or is planned for such radiotherapy or similar during the investigation period
  • For bilateral asymmetric candidates, subject already treated with a bone-anchored hearing solution on the side with the best bone conduction thresholds
  • Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Sentio system as determined by the investigator
  • Medical condition that contraindicates implant surgery or anesthesia as judged by the investigator
  • Untreated ongoing middle ear infection at the time of surgery
  • Known or suspected contact allergy to silicone or other material used in the Sentio system
  • Known condition that could jeopardize wound healing and skin condition, e.g. uncontrolled diabetes over time, as judged by the investigator
  • Known skin or scalp conditions that may preclude attachment or interfere with the usage of the sound processor
  • Evidence of conditions that would prevent good speech recognition potential as determined by good clinical judgment
  • Any other known condition that the investigator determines could interfere with compliance or investigation assessments
  • Known chronic or non-revisable vestibular or balance disorder
  • Use of active implantable or body worn device that for medical reasons cannot be removed or discontinued, such as CSF shunts, implantable cardiac pacemakers, defibrillators, or neurostimulators
  • Known need for frequent MRI investigations for follow-up of other diseases
  • Known abnormally progressive hearing loss
  • Any subject that according to the Declaration of Helsinki is deemed unsuitable for investigation enrolment

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is performed to collect safety and performance data supporting the use of the Sentio system in children below 12 years of age. The system is currently available on the market for patients 12 years and above. It is a prospective study conducted at eight European hospitals, aiming to treat 50 patients with a hearing loss than would benefit from treatment with a bone-anchored hearing system (BAHS). The primary objective of the study is to demonstrate that the Sentio system improves the hearing on the implanted ear, compared with the unaided situation.

A vizsgálat csoportja

  • Sentio systemA vizsgált kezelés

    Prospective, open label, single-arm multicentre investigation designed to follow clinical practice for bone conduction devices.

    Kezelés: Active transcutaneous bone conduction system

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multicenter, Single-arm Clinical Investigation of the Safety and Performance of the Sentio System in a Pediatric Population
A regiszteradat frissítve
2026. augusztus 14.